{"success":true,"data":{"pressRelease":{"id":"177599","rtpr_id":"nBw6WqbhTa-20261022","ticker":"ACET","exchange":"NASDAQ","all_tickers":["ACET"],"title":"Adicet Bio to Participate in Upcoming Investor Conferences","author":"Business Wire","published_at":"2026-10-22T20:00:00.298Z","article_body":"Adicet Bio to Participate in Upcoming Investor Conferences\n\nAdicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company\ndiscovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T\ntherapies for autoimmune diseases, hematologic malignancies and solid tumors,\ntoday announced that company management will participate in two upcoming\ninvestor conferences in November.\n\nDetails of the events are as follows:\n\nGuggenheim 3(rd) Annual Healthcare Innovation Conference, November 9-11, 2026,\nBoston, MA\n\n\n * Chen Schor, President and Chief Executive Officer, will participate in a\nfireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET\n\nJefferies Global Healthcare Conference, November 16-19, 2026, London, UK\n\n\n * Members of management will be available for 1x1 meetings on Thursday, November\n19, 2026\n\nThe live audio webcast of the fireside chat can be accessed on the Investors\nsection of Adicet Bio’s website at http://www.adicetbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.adicetbio.com%2F&esheet=54626934&newsitemid=20261022695225&lan=en-US&anchor=http%3A%2F%2Fwww.adicetbio.com&index=1&md5=dc20b8ecf6849eb7569e1d5ffc335dcb)\n. An archived replay will be available for 30 days following the presentation.\n\nAbout Adicet Bio, Inc.\n\nAdicet Bio, Inc. is a clinical-stage biotechnology company discovering and\ndeveloping a broad pipeline of allogeneic gamma delta T cell therapies,\nengineered with chimeric antigen receptors (CARs), alongside differentiated in\nvivo CAR-T therapies with the potential to redefine treatment across\nautoimmune diseases, hematologic malignancies and solid tumors. For more\ninformation, please visit our website at https://www.adicetbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adicetbio.com&esheet=54626934&newsitemid=20261022695225&lan=en-US&anchor=https%3A%2F%2Fwww.adicetbio.com&index=2&md5=b65033efb2dd6d4b80fb6c405e08699d)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261022695225/en/\n(https://www.businesswire.com/news/home/20261022695225/en/)\n\nInvestor and Media Contacts\n\nAnne Bowdidge\n\nabowdidge@adicetbio.com (mailto:abowdidge@adicetbio.com)\n\nPenelope Belnap\n\nPrecision AQ\n\nPenelope.belnap@precisionaq.com (mailto:Penelope.belnap@precisionaq.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6WqbhTa-20261022","title":"Adicet Bio to Participate in Upcoming Investor Conferences","author":"Business Wire","ticker":"ACET","created":"2026-10-22T20:00:00.298Z","tickers":["ACET"],"exchange":"NASDAQ","article_body":"Adicet Bio to Participate in Upcoming Investor Conferences\n\nAdicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company\ndiscovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T\ntherapies for autoimmune diseases, hematologic malignancies and solid tumors,\ntoday announced that company management will participate in two upcoming\ninvestor conferences in November.\n\nDetails of the events are as follows:\n\nGuggenheim 3(rd) Annual Healthcare Innovation Conference, November 9-11, 2026,\nBoston, MA\n\n\n * Chen Schor, President and Chief Executive Officer, will participate in a\nfireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET\n\nJefferies Global Healthcare Conference, November 16-19, 2026, London, UK\n\n\n * Members of management will be available for 1x1 meetings on Thursday, November\n19, 2026\n\nThe live audio webcast of the fireside chat can be accessed on the Investors\nsection of Adicet Bio’s website at http://www.adicetbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.adicetbio.com%2F&esheet=54626934&newsitemid=20261022695225&lan=en-US&anchor=http%3A%2F%2Fwww.adicetbio.com&index=1&md5=dc20b8ecf6849eb7569e1d5ffc335dcb)\n. An archived replay will be available for 30 days following the presentation.\n\nAbout Adicet Bio, Inc.\n\nAdicet Bio, Inc. is a clinical-stage biotechnology company discovering and\ndeveloping a broad pipeline of allogeneic gamma delta T cell therapies,\nengineered with chimeric antigen receptors (CARs), alongside differentiated in\nvivo CAR-T therapies with the potential to redefine treatment across\nautoimmune diseases, hematologic malignancies and solid tumors. For more\ninformation, please visit our website at https://www.adicetbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adicetbio.com&esheet=54626934&newsitemid=20261022695225&lan=en-US&anchor=https%3A%2F%2Fwww.adicetbio.com&index=2&md5=b65033efb2dd6d4b80fb6c405e08699d)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261022695225/en/\n(https://www.businesswire.com/news/home/20261022695225/en/)\n\nInvestor and Media Contacts\n\nAnne Bowdidge\n\nabowdidge@adicetbio.com (mailto:abowdidge@adicetbio.com)\n\nPenelope Belnap\n\nPrecision AQ\n\nPenelope.belnap@precisionaq.com (mailto:Penelope.belnap@precisionaq.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-22T20:00:00.805355772Z","server_sent_at_ms":1792699200805},"received_at":"2026-10-22T20:00:01.344Z","source_url":"https://www.businesswire.com/news/home/20261022695225/en/"},"analysis":{"id":"165540","press_release_id":"177599","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Adicet Bio announced management participation in two November investor conferences: the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London.\n\nCEO Chen Schor will give a fireside chat on November 10, with a live webcast and 30-day replay available; management will hold 1x1 meetings at Jefferies on November 19.\n\nThe release contains no clinical or financial updates and is routine investor-relations scheduling.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IR scheduling -- suppress unless the fireside chat surfaces new pipeline data."},"keyFigures":{},"namedEntities":{"people":[{"name":"Chen Schor","role":"President and CEO"},{"name":"Anne Bowdidge","role":"Investor and media contact"},{"name":"Penelope Belnap","role":"Precision AQ media contact"}],"products":[],"companies":[{"name":"Adicet Bio, Inc.","ticker":"ACET"},{"name":"Guggenheim","relationship":"conference host"},{"name":"Jefferies","relationship":"conference host"},{"name":"Precision AQ","relationship":"PR agency"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate announcement of participation in investor conferences with fireside chat and 1x1 meetings. No new clinical, financial, or strategic information disclosed."},"tickerRelevance":{"others":[],"primary":"ACET"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference participation notice","informationContent":"none"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Adicet Bio announced management participation in two November investor conferences: the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London.\n\nCEO Chen Schor will give a fireside chat on November 10, with a live webcast and 30-day replay available; management will hold 1x1 meetings at Jefferies on November 19.\n\nThe release contains no clinical or financial updates and is routine investor-relations scheduling.","key_figures":{},"named_entities":{"people":[{"name":"Chen Schor","role":"President and CEO"},{"name":"Anne Bowdidge","role":"Investor and media contact"},{"name":"Penelope Belnap","role":"Precision AQ media contact"}],"products":[],"companies":[{"name":"Adicet Bio, Inc.","ticker":"ACET"},{"name":"Guggenheim","relationship":"conference host"},{"name":"Jefferies","relationship":"conference host"},{"name":"Precision AQ","relationship":"PR agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T20:00:05.083Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference participation notice","informationContent":"none"}},"durationMs":3674,"modelName":"glm-5.3-flashx"}}